FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804172018> ?p ?o ?g. }

• W2804172018 abstract "Objective: Consumer electronics enable frequent and remote, test-based assessments and ‘passive’ continuous monitoring of motor symptoms and mobility in neurological patients. We determined the reliability, sensitivity and validity of smartphone-sensor derived features to quantify motor symptoms in Parkinson’s disease (PD) patients participating in a clinical trial, as a prerequisite for use in drug development and clinical practice. Background: Remote PD symptom monitoring complements and augments physician-administered rating scales by providing previously inaccessible insights into patients’ motor symptom severity and fluctuations with heightened ecological validity. However, the feasibility, reliability and validity of these measures in the clinical trial setting are unknown. Design/Methods: All 44 PD patients (cohorts 4–6) from the Phase Ib clinical trial NCT02157714 and 35 age and gender-matched healthy controls (HC) performed daily smartphone-based assessments of sustained phonation, resting and postural tremor, dexterity, balance and gait in their homes for 24 weeks (HC: 6 weeks). Participants also carried the smartphone throughout the day, resulting in 24,104h of passive monitoring data (HC: 8,614h). Investigational drug effects and longitudinal change were not evaluated. Clinically meaningful features were extracted from the smartphone sensor data and analyzed in-depth. Results: Features showed very good test-retest reliability, differentiated PD from HC participants and were significantly associated with symptom severity as measured by the MDS-UPDRS. Importantly, most features demonstrated subclinical sensitivity, i.e. significantly heightened signals in PD patients scored as having no symptoms at site visits compared to HC. Multiple passive monitoring features demonstrated reduced mobility in PD compared to HCs. Finally, a significant effect of concomitant symptomatic medication was detected with bradykinesia sensor features. Conclusions: Remote patient testing with smartphones is feasible and provides reliable, valid, sensitive measurements of motor symptom severity and decreased mobility in PD patients. Together with real-time data transfer and advanced analytics including machine learning, this technology provides a unique window into patients’ daily motor lives. Disclosure: Dr. Lipsmeier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Taylor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Kilchenmann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Wolf has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Scotland has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Schjodt-Eriksen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Cheng has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche TCRC Inc. Dr. Fernandez Garcia has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Siebourg-Polster has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Jin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche TCRC Inc. Dr. Soto has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prothena Biosciences Inc. Dr. Verselis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche TCRC Inc. Dr. Martin Facklam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Boess has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Boess holds stock and/or stock options in F. Hoffmann-La Roche Ltd. Dr. Koller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prothena Biosciences Inc. Dr. Koller holds stock and/or stock options in Prothena Biosciences Inc. Dr. Grundman holds stock and/or stock options in Prothena Biosciences Inc., which sponsored research in which Dr. Grundman was involved as an investigator. Dr. Grundman has received research support from Prothena Biosciences Inc. Dr. Monsch has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Vifor Pharma; Roche; AC Immune. Dr. Monsch has received research support from Vifor Pharma, Roche. Dr. Postuma has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biotie, Roche/Prothena, Teva Neurosciences, Jazz Pharmaceuticals, Novartis Canada, Theranexus, GE HealthCare, . Dr. Ghosh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Inc., E-Scape Bio. Dr. Kremer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Czech has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Czech has received compensation for serving on the Board of Directors of F. Hoffmann-La Roche Ltd. Dr. Gossens has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Gossens holds stock and/or stock options in F. Hoffmann-La Roche Ltd. Dr. Lindemann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd." @default.
• W2804172018 created "2018-06-01" @default.
• W2804172018 creator A5000633738 @default.
• W2804172018 creator A5002000248 @default.
• W2804172018 creator A5002425072 @default.
• W2804172018 creator A5006066023 @default.
• W2804172018 creator A5006230341 @default.
• W2804172018 creator A5007068261 @default.
• W2804172018 creator A5009707434 @default.
• W2804172018 creator A5012158017 @default.
• W2804172018 creator A5014646926 @default.
• W2804172018 creator A5022466380 @default.
• W2804172018 creator A5028557857 @default.
• W2804172018 creator A5031610769 @default.
• W2804172018 creator A5034101172 @default.
• W2804172018 creator A5035943996 @default.
• W2804172018 creator A5043312189 @default.
• W2804172018 creator A5055631779 @default.
• W2804172018 creator A5059154891 @default.
• W2804172018 creator A5065022440 @default.
• W2804172018 creator A5065043368 @default.
• W2804172018 creator A5067625175 @default.
• W2804172018 creator A5078865376 @default.
• W2804172018 creator A5083620898 @default.
• W2804172018 creator A5085591082 @default.
• W2804172018 date "2018-04-10" @default.
• W2804172018 modified "2023-09-26" @default.
• W2804172018 title "Remote patient testing with smartphones provides reliable, valid and sensitive measures of motor symptom severity in Parkinson’s disease patients (P3.046)" @default.
• W2804172018 hasPublicationYear "2018" @default.
• W2804172018 type Work @default.
• W2804172018 sameAs 2804172018 @default.
• W2804172018 citedByCount "0" @default.
• W2804172018 crossrefType "journal-article" @default.
• W2804172018 hasAuthorship W2804172018A5000633738 @default.
• W2804172018 hasAuthorship W2804172018A5002000248 @default.
• W2804172018 hasAuthorship W2804172018A5002425072 @default.
• W2804172018 hasAuthorship W2804172018A5006066023 @default.
• W2804172018 hasAuthorship W2804172018A5006230341 @default.
• W2804172018 hasAuthorship W2804172018A5007068261 @default.
• W2804172018 hasAuthorship W2804172018A5009707434 @default.
• W2804172018 hasAuthorship W2804172018A5012158017 @default.
• W2804172018 hasAuthorship W2804172018A5014646926 @default.
• W2804172018 hasAuthorship W2804172018A5022466380 @default.
• W2804172018 hasAuthorship W2804172018A5028557857 @default.
• W2804172018 hasAuthorship W2804172018A5031610769 @default.
• W2804172018 hasAuthorship W2804172018A5034101172 @default.
• W2804172018 hasAuthorship W2804172018A5035943996 @default.
• W2804172018 hasAuthorship W2804172018A5043312189 @default.
• W2804172018 hasAuthorship W2804172018A5055631779 @default.
• W2804172018 hasAuthorship W2804172018A5059154891 @default.
• W2804172018 hasAuthorship W2804172018A5065022440 @default.
• W2804172018 hasAuthorship W2804172018A5065043368 @default.
• W2804172018 hasAuthorship W2804172018A5067625175 @default.
• W2804172018 hasAuthorship W2804172018A5078865376 @default.
• W2804172018 hasAuthorship W2804172018A5083620898 @default.
• W2804172018 hasAuthorship W2804172018A5085591082 @default.
• W2804172018 hasConcept C113280763 @default.
• W2804172018 hasConcept C121332964 @default.
• W2804172018 hasConcept C126322002 @default.
• W2804172018 hasConcept C138496976 @default.
• W2804172018 hasConcept C151800584 @default.
• W2804172018 hasConcept C15744967 @default.
• W2804172018 hasConcept C163258240 @default.
• W2804172018 hasConcept C1862650 @default.
• W2804172018 hasConcept C2779134260 @default.
• W2804172018 hasConcept C2779734285 @default.
• W2804172018 hasConcept C30036603 @default.
• W2804172018 hasConcept C43214815 @default.
• W2804172018 hasConcept C535046627 @default.
• W2804172018 hasConcept C62520636 @default.
• W2804172018 hasConcept C71924100 @default.
• W2804172018 hasConcept C83849319 @default.
• W2804172018 hasConcept C99508421 @default.
• W2804172018 hasConceptScore W2804172018C113280763 @default.
• W2804172018 hasConceptScore W2804172018C121332964 @default.
• W2804172018 hasConceptScore W2804172018C126322002 @default.
• W2804172018 hasConceptScore W2804172018C138496976 @default.
• W2804172018 hasConceptScore W2804172018C151800584 @default.
• W2804172018 hasConceptScore W2804172018C15744967 @default.
• W2804172018 hasConceptScore W2804172018C163258240 @default.
• W2804172018 hasConceptScore W2804172018C1862650 @default.
• W2804172018 hasConceptScore W2804172018C2779134260 @default.
• W2804172018 hasConceptScore W2804172018C2779734285 @default.
• W2804172018 hasConceptScore W2804172018C30036603 @default.
• W2804172018 hasConceptScore W2804172018C43214815 @default.
• W2804172018 hasConceptScore W2804172018C535046627 @default.
• W2804172018 hasConceptScore W2804172018C62520636 @default.
• W2804172018 hasConceptScore W2804172018C71924100 @default.
• W2804172018 hasConceptScore W2804172018C83849319 @default.
• W2804172018 hasConceptScore W2804172018C99508421 @default.
• W2804172018 hasLocation W28041720181 @default.
• W2804172018 hasOpenAccess W2804172018 @default.
• W2804172018 hasPrimaryLocation W28041720181 @default.
• W2804172018 hasRelatedWork W2059492720 @default.
• W2804172018 hasRelatedWork W2514450126 @default.
• W2804172018 hasRelatedWork W2608264852 @default.
• W2804172018 hasRelatedWork W2898394273 @default.
• W2804172018 hasRelatedWork W2988592393 @default.
• W2804172018 hasRelatedWork W3157401163 @default.
• W2804172018 hasRelatedWork W3164047571 @default.

• next